The Europe Recombinant Proteins Market would witness market growth of 10.4% CAGR during the forecast period (2022-2028).
To boost research output and expand their product offerings for income creation, major firms are investing in their R&D initiatives. For instance, in 2021, Merck KGaA expended USD 2.44 billion (EUR 2.4 billion) on research and development, with the majority of the budget going toward healthcare and life sciences.
Such cases are anticipated to strengthen the argument for the expansion of R&D efforts and show the companies' commitment to making a difference for patients. Such corporate activities will probably support industry expansion in the upcoming years. Cloning antibody gene libraries into phage vectors and enabling the phages to infect a host cell line are both steps in the manufacture of recombinant antibodies.
Recombinant antibody development for COVID-19 infection is another area of business involvement. For instance, Sanofi and GSK began a new phase 2b trial with 720 volunteers who were 18 years of age or older in February 2021 to determine the best antigen dosage for the adjuvanted recombinant protein COVID-19 vaccine candidate's phase 3 evaluation.
The Department of Health has been the central government agency primarily in charge of establishing policies for the English healthcare and social care systems. The particular roles & responsibilities of the Department have changed as a result of the 2012 Health and Social Care Act, moving away from direct obligation for delivering the NHS to one that now offers strategic direction, serves as caretaker for the health and care system, evolves national policies, and offer guidance.
The Germany market dominated the Europe Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $170.7 million by 2028. The UK market is anticipated to grow at a CAGR of 9.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 11.2% during (2022 - 2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Recombinant Proteins Market will Hit $2.6 Billion by 2028, at a CAGR of 10.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
By Product
By End User
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
